Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naproxen + tramadol is a combination of two analgesic drugs used together for the management of moderate to severe pain, particularly when monotherapy is insufficient. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and inflammation. Tramadol is an atypical opioid analgesic that acts as an agonist at the μ-opioid receptor and also inhibits the reuptake of serotonin and norepinephrine, contributing to its pain-relieving effects. The combination can provide additive or synergistic pain relief, allowing for lower doses of each drug while maintaining efficacy[4][2][5]. This approach may reduce the risk of side effects associated with higher doses of either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naproxen + tramadol.